Current Malaria Treatment Fails in Cambodia Due to Drug-Resistant Parasites || National Institute of Allergy and Infectious Diseases (NIAID)

Friday January 8, 2016

Current Malaria Treatment Fails in Cambodia Due to Drug-Resistant Parasites

New findings from NIAID confirm that the first-line malaria treatment in Cambodia, dihydroartemisinin-piperaquine, has failed in certain provinces due to parasite resistance to artemisinin and piperaquine. Additional study findings show parasites had an increased susceptibility to artesunate, a form of artemisinin, plus mefloquine, a different long-acting partner drug. These findings informed new WHO guidelines reinstating artesunate plus mefloquine as the first-line therapy in Cambodia where dihydroartemisinin-piperaquine has failed.